1. Published

   Alcohol, drugs, sex and violence: health risks and consequences in young British holidaymakers to the Balearics

   Hughes, K., Bellis, M. A., Whelan, G., Calafat, A., Juan, M. & Blay, N., 2009, In: Adicciones. 21, 4, p. 265-77 13 p.

   Research output: Contribution to journal › Article › peer-review

2. Published

   Alcohol, nightlife and violence: the relative contributions of drinking before and during nights out to negative health and criminal justice outcomes

   Hughes, K., Anderson, Z., Morleo, M. & Bellis, M. A., Jan 2008, In: Addiction. 103, 1, p. 60-5 6 p.

   Research output: Contribution to journal › Article › peer-review

3. Published

   Aligning Cultural Safety and Language Appropriate Practice: new horizons for nurse education.

   Roberts, G. W., Roberts, G. & Irvine, F., 1 Jan 2010.

   Research output: Contribution to conference › Paper

4. Published

   Aligning cultural safety and language appropriate practice: new horizons for nurse education in a global community.

   Roberts, G. W., Roberts, G. & Irvine, F., 1 Jan 2010.

   Research output: Contribution to conference › Paper

5. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

6. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

7. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

   Research output: Book/Report › Commissioned report

8. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

   Research output: Book/Report › Commissioned report

9. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

10. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

11. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

12. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

13. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

14. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

15. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

16. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

17. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

18. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

19. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

20. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

21. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

22. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

23. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

24. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

25. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

26. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

27. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

28. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

29. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

30. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

31. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

32. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

33. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

34. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

35. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

36. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

37. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

38. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

39. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

40. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

41. Published

    All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

42. Published

    Alleviating anxiety in patients prior to MRI: A pilot single-centre single-blinded randomised controlled trial to compare video demonstration or telephone conversation with a radiographer versus routine intervention

    Tugwell, J. R., Goulden, N. & Mullins, P., May 2018, In: Radiography. 24, 2, p. 122-129

    Research output: Contribution to journal › Article › peer-review

43. Published

    Alpha Values as a Function of Sample Size, Effect Size, and Power: Accuracy over Inference

    Bradley, M. T. & Brand, A., Jun 2013, In: Psychological Reports. 112, 3, p. 835-844

    Research output: Contribution to journal › Article › peer-review

44. Published

    Alpha adrenoceptor agonist-induced microcirculatory oscillations are reduced in diabetic neuropathy.

    Schmiedel, O., Nurmikko, T. J., Schroeter, M. L., Whitaker, R. & Harvey, J. N., 1 Aug 2008, In: Microvascular Research. 76, 2, p. 124-131

    Research output: Contribution to journal › Article › peer-review

45. Published

    An Art Gallery Access Programme for people with dementia: ‘You do it for the moment’

    Bird, M. J., MacPherson, S., Bird, M., Anderson, K., Davis, T. & Blair, A., 1 Sept 2009, In: Aging and Mental Health. 13, 5, p. 744-752

    Research output: Contribution to journal › Article › peer-review

46. Published

    An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients

    Neal, R. D., Baird, R., Banks, I., Cameron, D., Chester, J., Earl, H., Flannagan, M., Januszewski, A., Kennedy, R., Payne, S., Samuel, E., Taylor, H., Agarwal, R., Ahmed, S., Archer, C., Board, R., Carser, J., Copson, E., Cunningham, D., Coleman, R., Glaser, A., Griffiths, R., Hall, G., Hall, M., Harari, D., Hawkins, M., Hill, M., Johnson, P., Jones, A., Kalsi, T., Karapanagiotou, E., Kemp, Z., Mansi, J., Marshall, E., Mitchell, A., Moe, M., Michie, C., Neal, R., Newsom-Davis, T., Norton, A., Osborne, R., Patel, G., Radford, J., Ring, A., Shaw, E., Skinner, R., Stark, D., Turnbull, S., Velikova, G., White, J., Young, A., Joffe, J. & Selby, P., 5 Jan 2016, In: Ecancermedical Science. 10, 608

    Research output: Contribution to journal › Article › peer-review

47. Published

    An EU Code of Ethics for Socio-Economic Research

    Huws, U., Dench, S. & Iphofen, R., 1 Jan 2004, Institute for Employment Studies.

    Research output: Book/Report › Book

48. Published

    An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer

    Ezeofor, V., Spencer, L., Rogers, S. N., Kanatas, A., Lowe, D., Semple, C. J., Hanna, J. R., Yeo, S. T. & Edwards, R. T., May 2022, In: PharmacoEconomics - Open. 6, 3, p. 389-403 15 p.

    Research output: Contribution to journal › Article › peer-review

49. Published

    An Integrated Care Pathway for the Problem Drinker in the Community.

    Sims, J. & Iphofen, R., 1 Mar 2003, In: Drug and Alcohol Professional. 3, 1, p. 24-30

    Research output: Contribution to journal › Article › peer-review

50. Published

    An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation

    Sackley, C., Walker, M., Burton, C., Watkins, C., Mant, J., Roalfe, A., Wheatley, K., Sheehan, B., Sharp, L., Stant, K. E., Fletcher-Smith, J., Steel, K., Barton, G., Irving, L. & Peryer, G., Feb 2016, In: Health Technology Assessment. 20, 15

    Research output: Contribution to journal › Article › peer-review